Application of IRF4 inhibitor in treatment of non-alcoholic steatohepatitis

Through IRF4 inhibitors, especially engagliflozin and β-hydroxybutyric acid, inhibit CD8+ T cell activation and inflammatory factor secretion, the problem of insufficient regulation of the liver immune environment in existing MASH treatment is solved, and more effective treatment is achieved Effects and longer lasting effects.

CN118903420APending Publication Date: 2024-11-08SOUTHERN MEDICAL UNIVERSITY
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410876002.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-02
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing non-alcoholic steatohepatitis (MASH) treatment drugs can only target fat deposition in the liver, and fail to effectively regulate the liver immune environment, resulting in poor treatment results.

Method used

Develop IRF4 inhibitors to regulate abnormal liver immune status by inhibiting the activation and function of CD8+ T cells, and use empagliflozin and β-hydroxybutyric acid as IRF4 inhibitors to reduce IRF4 expression levels to inhibit inflammatory factor secretion and GZMB expression .

Benefits of technology

Effectively slow down the progress of MASH, improve treatment effect, improve the liver immune environment, reduce inflammatory response and fibrosis, and provide a more lasting and comprehensive treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004923041010000071
    Figure BDA0004923041010000071
  • Figure BDA0004923041010000081
    Figure BDA0004923041010000081
  • Figure BDA0004923041010000101
    Figure BDA0004923041010000101
Patent Text Reader

Abstract

The invention belongs to the technical field of biomedicine, discloses application of an IRF4 inhibitor to treatment of non-alcoholic steatohepatitis, and particularly discloses application of the IRF4 inhibitor to preparation of a medicine for treating the non-alcoholic steatohepatitis. The invention proposes that the IRF4 inhibitor can inhibit the activation and function of CD8 + T cells in the MASH liver for the first time, so that the abnormal immune state of the liver is regulated, and the progress of the MASH is slowed down.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedical technology, and in particular relates to the application of an IRF4 inhibitor in the treatment of non-alcoholic fatty hepatitis. Background Art

[0002] Currently, the prevalence of non-alcoholic fatty liver disease (MAFLD) is increasing rapidly. Non-alcoholic steatohepatitis (MASH) is the active state of MAFLD. During the progression of the disease, the lipid load, oxidative stress and inflammation of hepatocytes work together to cause hepatocyte death, thereby leading to liver damage, further aggravating liver inflammation and tissue fibrosis. Among them, the important role of liver inflammation in the progression of MASH disease indicates that the liver environment rich in immune cells is a key factor affecting the severity of MASH disease. An important subset of lymphocytes, cytotoxic CD8 + T cells mainly produce cytotoxic molecules such as GZMB, IFN-γ, TNF, and perforin. During MASH in mice and humans, the number of liver CD8+ T cells increases, especially CXCR6 + CD8 + In the diet-induced MASH mouse model, CD8 + T cell deficiency can reduce liver damage, indicating that T cells are indispensable in the pathogenesis of MASH. Controlling liver T cell infiltration and function can be used as a new therapeutic entry point. However, the only FDA-approved therapeutic drug for MASH is the thyroxine receptor (THR)-b selective agonist, which targets fat deposits in the liver and reduces serum cholesterol and triglyceride levels, rather than treating the imbalance of the liver immune environment. Therefore, it is of great prospect to explore a drug that can improve the immune environment during the progression of MASH.

[0003] IRF4 is a hematopoietic-specific transcription factor that is essential for the development and function of lymphoid and myeloid lineages, so its expression is limited to immune cells such as T cells, B cells, and macrophages. Previous studies have shown that myeloid knockout of Irf4 can alleviate renal fibrosis after ischemic injury by reducing the recruitment and colonization of macrophages, suggesting that specific inhibition of IRF4 expression in immune cells can improve tissue damage, function, and prognosis. Summary of the invention

[0004] The present invention proposes that IRF4 inhibitors can inhibit CD8 + The activation and function of T cells regulate the abnormal immune state of the liver and effectively slow down the progression of MASH. It is proposed that empagliflozin (a sodium-glucose co-transporter 2 inhibitor) and β-hydroxybutyrate can be used as IRF4 inhibitors, and their feasibility in the treatment of MASH has been confirmed.

[0005] The purpose of the first aspect of the present invention is to provide use of an IRF4 inhibitor in the preparation of a medicament for treating non-alcoholic steatohepatitis.

[0006] The second aspect of the present invention aims to provide an IRF4 inhibitor for use in the preparation of a CD8 + Application of the product for T cell activation.

[0007] The third aspect of the present invention aims to provide the use of an IRF4 inhibitor in the preparation of a product for inhibiting the secretion of inflammatory factors.

[0008] The fourth aspect of the present invention aims to provide use of an IRF4 inhibitor in the preparation of a product for inhibiting the expression of GZMB.

[0009] The fifth aspect of the present invention is to provide a method for inhibiting CD8 + Methods for activation of T cells.

[0010] The sixth aspect of the present invention aims to provide the use of empagliflozin and / or β-hydroxybutyric acid in the preparation of IRF4 inhibitors.

[0011] In order to achieve the above object, the technical solution adopted by the present invention is:

[0012] The first aspect of the present invention provides use of an IRF4 inhibitor in the preparation of a medicament for treating non-alcoholic steatohepatitis.

[0013] In some embodiments of the present invention, the IRF4 inhibitor inhibits CD8 + The activation and function of T cells regulate the abnormal immune state of the liver and achieve the purpose of treating non-alcoholic fatty hepatitis.

[0014] In some embodiments of the present invention, the IRF4 inhibitor is at least one of a substance that inhibits the activity of IRF4, a substance that degrades IRF4, and a substance that reduces the expression level of IRF4.

[0015] In some embodiments of the present invention, the substance that reduces the expression level of IRF4 is at least one of a1) to a5):

[0016] a1) siRNA, dsRNA, miRNA, sgRNA, ribozyme or shRNA targeting IRF4;

[0017] a2) a nucleic acid molecule encoding the siRNA, dsRNA, miRNA, sgRNA, ribozyme or shRNA targeting IRF4 described in a2);

[0018] a3) an expression cassette, a vector or a transgenic cell line comprising the nucleic acid molecule described in a2);

[0019] a4) Small molecule drugs targeting IRF4;

[0020] a5) Blocking IRF4 protein and / or IRF4 protein intermediate IRF4 inhibitory polypeptide.

[0021] In some embodiments of the present invention, the substance that reduces the expression level of IRF4 includes empagliflozin and / or β-hydroxybutyrate.

[0022] In some embodiments of the present invention, the effective dose of the IRF4 inhibitor in the drug is 1 to 20 μM.

[0023] In some preferred embodiments of the present invention, the effective dose of the IRF4 inhibitor in the drug is 5 to 15 μM.

[0024] In a second aspect of the present invention, an IRF4 inhibitor is provided for preparing a method for inhibiting CD8 + Application of the product for T cell activation.

[0025] Application of IRF4 inhibitors in inhibiting the activation of CD8+ T cells.

[0026] In some embodiments of the present invention, the IRF4 inhibitor is at least one of a substance that inhibits the activity of IRF4, a substance that degrades IRF4, and a substance that reduces the expression level of IRF4.

[0027] In some embodiments of the present invention, the substance that reduces the expression level of IRF4 is at least one of a1) to a5):

[0028] a1) siRNA, dsRNA, miRNA, sgRNA, ribozyme or shRNA targeting IRF4;

[0029] a2) a nucleic acid molecule encoding the siRNA, dsRNA, miRNA, sgRNA, ribozyme or shRNA targeting IRF4 described in a2);

[0030] a3) an expression cassette, a vector or a transgenic cell line comprising the nucleic acid molecule described in a2);

[0031] a4) Small molecule drugs targeting IRF4;

[0032] a5) Blocking IRF4 protein and / or IRF4 protein intermediate IRF4 inhibitory polypeptide.

[0033] In some embodiments of the present invention, the substance that reduces the expression level of IRF4 includes empagliflozin and / or β-hydroxybutyrate.

[0034] In some embodiments of the present invention, the effective dose of the IRF4 inhibitor in the drug is 1 to 20 μM.

[0035] In some preferred embodiments of the present invention, the effective dose of the IRF4 inhibitor in the drug is 5 to 15 μM.

[0036] The third aspect of the present invention provides the use of an IRF4 inhibitor in the preparation of a product for inhibiting the secretion of inflammatory factors.

[0037] Application of IRF4 inhibitors in inhibiting the secretion of inflammatory factors.

[0038] In some embodiments of the present invention, the inflammatory factors include TNF-α and IFN-γ.

[0039] In some embodiments of the present invention, the IRF4 inhibitor is at least one of a substance that inhibits the activity of IRF4, a substance that degrades IRF4, and a substance that reduces the expression level of IRF4.

[0040] In some embodiments of the present invention, the substance that reduces the expression level of IRF4 is at least one of a1) to a5):

[0041] a1) siRNA, dsRNA, miRNA, sgRNA, ribozyme or shRNA targeting IRF4;

[0042] a2) a nucleic acid molecule encoding the siRNA, dsRNA, miRNA, sgRNA, ribozyme or shRNA targeting IRF4 described in a2);

[0043] a3) an expression cassette, a vector or a transgenic cell line comprising the nucleic acid molecule described in a2);

[0044] a4) Small molecule drugs targeting IRF4;

[0045] a5) Blocking IRF4 protein and / or IRF4 protein intermediate IRF4 inhibitory polypeptide.

[0046] In some embodiments of the present invention, the substance that reduces the expression level of IRF4 includes empagliflozin and / or β-hydroxybutyrate.

[0047] In some embodiments of the present invention, the effective dose of the IRF4 inhibitor in the drug is 1 to 20 μM.

[0048] In some preferred embodiments of the present invention, the effective dose of the IRF4 inhibitor in the drug is 5 to 15 μM.

[0049] A fourth aspect of the present invention provides use of an IRF4 inhibitor in the preparation of a product for inhibiting the expression of GZMB.

[0050] Use of IRF4 inhibitors in inhibiting the expression of GZMB.

[0051] In some embodiments of the present invention, the IRF4 inhibitor is at least one of a substance that inhibits the activity of IRF4, a substance that degrades IRF4, and a substance that reduces the expression level of IRF4.

[0052] In some embodiments of the present invention, the substance that reduces the expression level of IRF4 is at least one of a1) to a5):

[0053] a1) siRNA, dsRNA, miRNA, sgRNA, ribozyme or shRNA targeting IRF4;

[0054] a2) a nucleic acid molecule encoding the siRNA, dsRNA, miRNA, sgRNA, ribozyme or shRNA targeting IRF4 described in a2);

[0055] a3) an expression cassette, a vector or a transgenic cell line comprising the nucleic acid molecule described in a2);

[0056] a4) Small molecule drugs targeting IRF4;

[0057] a5) Blocking IRF4 protein and / or IRF4 protein intermediate IRF4 inhibitory polypeptide.

[0058] In some embodiments of the present invention, the substance that reduces the expression level of IRF4 includes empagliflozin and / or β-hydroxybutyrate.

[0059] In some embodiments of the present invention, the effective dose of the IRF4 inhibitor in the drug is 1 to 20 μM.

[0060] In some preferred embodiments of the present invention, the effective dose of the IRF4 inhibitor in the drug is 5 to 15 μM.

[0061] The fifth aspect of the present invention provides a method for inhibiting CD8 + A method for activating T cells, comprising: + Steps in the exposure of T cells to IRF4 inhibitors.

[0062] In some embodiments of the present invention, the IRF4 inhibitor is at least one of a substance that inhibits the activity of IRF4, a substance that degrades IRF4, and a substance that reduces the expression level of IRF4.

[0063] In some embodiments of the present invention, the substance that reduces the expression level of IRF4 is at least one of a1) to a5):

[0064] a1) siRNA, dsRNA, miRNA, sgRNA, ribozyme or shRNA targeting IRF4;

[0065] a2) a nucleic acid molecule encoding the siRNA, dsRNA, miRNA, sgRNA, ribozyme or shRNA targeting IRF4 described in a2);

[0066] a3) an expression cassette, a vector or a transgenic cell line comprising the nucleic acid molecule described in a2);

[0067] a4) Small molecule drugs targeting IRF4;

[0068] a5) Blocking IRF4 protein and / or IRF4 protein intermediate IRF4 inhibitory polypeptide.

[0069] In some embodiments of the present invention, the substance that reduces the expression level of IRF4 includes empagliflozin and / or β-hydroxybutyrate.

[0070] In some embodiments of the present invention, the effective dose of the IRF4 inhibitor in the drug is 1 to 20 μM.

[0071] In some preferred embodiments of the present invention, the effective dose of the IRF4 inhibitor in the drug is 5 to 15 μM.

[0072] A sixth aspect of the present invention provides the use of empagliflozin and / or β-hydroxybutyric acid in the preparation of an IRF4 inhibitor.

[0073] The beneficial effects of the present invention are:

[0074] In the treatment of MASH, a new drug treatment regimen is proposed to regulate the abnormal immune state of the liver and effectively slow down the progression of MASH. Compared with the current FDA-approved therapeutic drugs, the IRF4 inhibitor proposed in this invention can more comprehensively affect the disease mechanism of MASH, thereby bringing the following benefits:

[0075] 1. Improved therapeutic effect: The IRF4 inhibitor proposed in this invention can inhibit CD8 + The activation and function of T cells regulate the abnormal immune state of the liver. Compared with the current drugs that only target the removal of fat deposits in the liver, this treatment strategy more directly intervenes in the pathogenesis of MASH and is expected to improve the treatment effect.

[0076] 2. Durability of efficacy: By inhibiting IRF4 in immune cells, this approach may improve the immune environment of the liver, making the therapeutic effect more durable. Compared with the side effects and unstable efficacy of some drugs, this regulation of the immune environment may bring longer-term efficacy.

[0077] 3. Comprehensive treatment: Compared with current treatment methods, the IRF4 inhibitor proposed in the present invention can comprehensively regulate the immune environment of the liver, thereby slowing down the progression of MASH while also alleviating multiple pathological processes such as inflammatory response and fibrosis, making the treatment effect more comprehensive.

[0078] 4. Drug diversity: The IRF4 inhibitors proposed in the present invention, such as empagliflozin and β-hydroxybutyric acid, are existing and widely used drugs and compounds, and their feasibility and safety are relatively high. This treatment strategy based on existing drugs may be more easily accepted by the market and reduce R&D risks and time costs.

[0079] These benefits are based on an understanding of the mechanism of action of IRF4 in immune cells. + The differentiation and function of T cells, in turn, regulate the abnormal immune state of the liver, thereby slowing down the progression of MASH. Previous studies have shown that the inhibition of IRF4 in specific immune cells can improve tissue damage and function, so the regulation of the immune environment in the treatment of MASH may become a new treatment strategy. Therefore, the treatment scheme based on IRF4 inhibition proposed in the present invention is practical and feasible, and in theory can bring obvious therapeutic effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0080] Figure 1 This is the effect of IRF4 overexpression on the expression of GZMB, TNF-a and IFN-g related genes in CD8 T cells.

[0081] Figure 2 These are the results of the effects of empagliflozin and β-hydroxybutyrate on IRF4 gene expression.

[0082] Figure 3 The results show the effects of empagliflozin and β-hydroxybutyrate on the transcription of IRF4. The scale bar is 50 μm.

[0083] Figure 4 For the effect of empagliflozin on CD8 + Results of flow cytometry analysis of the effects of early T cell activation.

[0084] Figure 5 For the effect of empagliflozin on CD8 + Flow cytometry analysis of the effects on late T cell activation and function.

[0085] Figure 6 Effect of empagliflozin on early activated and late activated CD8 + The effect of T cell ratio on flow cytometry results.

[0086] Figure 7 The NAS score, Masson staining and α-SMA immunohistochemical staining of the liver of MASH mice after empagliflozin intervention; A is HE staining Masson staining (showing collagen fibers) and α-SMA (a marker of stellate cell activation) immunohistochemical staining of mouse liver, and the representative figure is shown. B is the NAS score (lipid deposition, intralobular inflammation, hepatocyte ballooning). C is the statistics of Masson and α-SMA positive areas. The scale length is 50 microns.

[0087] Figure 8 The results show the effects of empagliflozin on the liver infiltration and effector function of CD8 T cells in MASH mice. The scale bar is 50 μm.

[0088] Fig. 9 Effect of β-OHB on primary CD8 + The results of the study affected T cell activation and function.

[0089] Fig.10 NAS score, Masson staining, and α-SMA immunohistochemical staining of the liver of MASH mice after 1,3-BD intervention. The scale bar is 50 μm.

[0090] Fig.11 Results show the effects of 1,3-BD on the liver infiltration and effector function of CD8 T cells in MASH mice. Scale bar length: 50 μm. DETAILED DESCRIPTION

[0091] The present invention is further described in detail below through specific examples.

[0092] It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.

[0093] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0094] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0095] Terminology explanation:

[0096] Metabolic-associated fatty liver disease (MAFLD): It is a liver disease caused by metabolic dysfunction. The pathogenesis of MAFLD is fat accumulation in the liver, and one of the following three conditions is met: overweight / obesity, type 2 diabetes (T2DM), metabolic syndrome. MAFLD ranges from the relatively benign metabolic dysfunction-associated fatty liver (MAFL) to the more pathologically severe metabolic dysfunction-associated steatohepatitis (MASH), and in some cases, it can progress to cirrhosis or hepatocellular carcinoma.

[0097] Interferon regulatory factors (IRFs) are a group of transcription factors associated with gene expression regulation and immune response. IRF4 is a member of the IRF family and is known for its role in regulating immune cell development and function.

[0098] Experimental methods

[0099] 1. Flow Cytometry

[0100] Surface staining: Prepare the reaction system according to Table 1, 50 μL / well, stain at 4°C for 30 min.

[0101] Table 1 Surface dyeing reaction system

[0102]

[0103]

[0104] Intracellular staining: preheat 4% PFA in a 37°C water bath; add 200 μL / well of PBS with a dispenser, blow evenly, cover, centrifuge at 400g for 5 min, and discard the supernatant; add 100 μL / well of 4% PFA with a dispenser, blow gently evenly, and place at room temperature and away from light for 5 min; add 150 μL / well of PBS, cover, centrifuge at 1500g for 5 min, and discard the supernatant; add 100 μL / well of 0.1% TritonX-100, blow gently evenly; place at room temperature and away from light for 5 min; add 150 μL / well of PBS, cover, centrifuge at 2000g for 5 min, and discard the supernatant; add antibodies (GranzmB-Pecy7, dilution ratio 1:500; 20% BSA, dilution ratio 1:200), 50 μL / well, stain at 4°C for 2 h; add 200 μL / well of PBS, mix well, transfer to flow tube, and detect on the machine.

[0105] 2. Construction of MASH mouse model with high-fat, high-sugar, high-cholesterol diet (HFHC diet, Research Diets, D09100310)

[0106] Forty 7-week-old male C57 mice were purchased from Beijing Weitonglihua. After one week of adaptive feeding, they were randomly divided into four groups, with 10 mice in each group:

[0107] Group A: fed with normal maintenance feed (Synergy Biological, 1010002) for 28 weeks;

[0108] Group B: fed with HFHC diet for 28 weeks;

[0109] Group C: After being fed with HFHC diet for 20 weeks, the mice were fed with feed containing 30 mg / kg Empagliflozin (MEPA) for 8 weeks;

[0110] Group D: After being fed with HFHC diet for 20 weeks, the mice were fed with water containing 10% 1,3-BD (a precursor of β-hydroxybutyrate that can be converted into β-hydroxybutyrate in the body) for 8 weeks.

[0111] 3. HE staining and NAS scoring

[0112] Liver samples were fixed in formalin and sliced ​​for subsequent HE and immunohistochemical staining; the efficacy of MASH morbidity was evaluated by the non-alcoholic fatty liver disease (MAFLD) activity score (NAS) of liver HE staining, and the scoring criteria were as follows: ① Hepatocyte fatty degeneration: 0 points (<5%); 1 point (5%-33%); 2 points (34%-66%); 3 points (>66%); ② Intralobular inflammation (necrotic foci counted under a 20x microscope): 0 points, none; 1 point (<2); 2 points (2-4); 3 points (>4); ③ Hepatocyte ballooning: 0 points, none; 1 point, rare; 2 points, common. NAS<3 points can exclude MASH, NAS>4 points can diagnose MASH, and those between the two are possible MASH. It is stipulated that those without intralobular inflammation, ballooning and fibrosis but with liver fatty degeneration>33% are NAFL, and those with fatty degeneration that does not reach this level are only called hepatocyte fatty degeneration.

[0113] 4. Immunohistochemistry

[0114] After completing the paraffin section, bake the slices in a 70℃ oven for 2h. After returning to room temperature, the subsequent experiments can be carried out immediately. Dewaxing: dewaxing in a xylene dye tank 3 times, 10min each time; hydration: gradient ethanol (100%, 100%, 95%, 90%, 80%, 70%) step by step, the time is 3min, wash with tap water for 2min, and wash with 1×PBS for 3min. Antigen repair: prepare citric acid antigen repair solution, repair with a pressure cooker, drive the pressure reducing valve when the pressure reaches a certain level, adjust the power to 1200W, and time 5-10min. Cool naturally to room temperature. Eliminate endogenous peroxidase activity in cells: wash with PBS 3 times, 5min each time, and then place in 3% hydrogen peroxide at room temperature for 25min to prevent nonspecific staining. Wash the slides 3 times with PBS, 5min each time. The histochemical pen circle is about 2mm away from the tissue. Drop ready-to-use normal goat serum around the tissue, let it slowly flow into the tissue, and leave it at room temperature for about 30min. Gently shake off the goat serum, add 30-40 μL of primary antibody working solution (CD8: CellSignaling Technology#98941, concentration 1:500; α-SMA: ABclonal, #A17910, concentration 1:500; GZMB: Abcam#ab53097, concentration 1:500) according to the size of the tissue, place in a wet box, and incubate at 4°C overnight. The next day, wash the slides 3 times with PBS, 5 minutes each time. Add the secondary antibody working solution (HRP-conjugated goat anti-rabbit IgG antibody, Xinbosheng, concentration 1:1000) to the tissue and incubate at room temperature for 90 minutes. Wash the slides 3 times with PBS, 5 minutes each time. Prepare AEC color development solution according to the corresponding proportion, and observe the color development of the slices under a microscope. Drop an appropriate amount of hematoxylin, stain for 10-20 seconds, observe the degree of nuclear staining under a microscope, and stop in distilled water in time. To prevent the nuclei from being stained too dark or too light, wash the sections with water for 5 minutes to remove impurities.

[0115] 5.Masson staining

[0116] Dewax and hydrate the paraffin sections in the same way as before; hematoxylin staining of cell nuclei: Weigert iron hematoxylin staining in the Masson staining kit for 5 minutes, rinse with tap water; 1% hydrochloric acid ethanol differentiation for a few seconds, rinse with tap water, and rinse with running water for 5 minutes to return to blue; Ponceau staining: Ponceau staining solution in the Masson staining kit for 5 to 10 minutes, and quickly rinse with distilled water. During the above operation, a weak acid working solution is prepared in a ratio of distilled water: weak acid solution = 2:1, and the weak acid working solution is used for washing for 1 minute. Wash with phosphomolybdic acid solution for 1 to 2 minutes. Wash with the prepared weak acid working solution for 1 minute. Directly put into aniline blue staining solution for staining for 1 to 2 minutes. Wash with the prepared weak acid working solution for 1 minute. Dehydration: Rapid dehydration with 95% ethanol, dehydration with anhydrous ethanol 3 times, 5 to 10 seconds each time. Xylene transparent 3 times, 1 to 2 minutes each time. Neutral gum sealing.

[0117] Note: Staining results: cell nuclei and collagen fibers are blue, and cytoplasm is red.

[0118] 6. RNA extraction and real-time fluorescence quantitative PCR

[0119] 6.1 RNA extraction

[0120] After collecting T cells, centrifuge at 400g for 5min, discard the supernatant and keep the precipitate; add 500μL Trizol to the EP tube, gently blow to mix, and let it stand on ice for 10min; add 100μL chloroform (Trizol: chloroform = 5:1) to the EP tube, cover the lid and shake for 15s, let it stand at room temperature for 10min, and then centrifuge at 12000rpm at 4 degrees for 15min; after centrifugation, it is divided into 3 layers, and the supernatant aqueous phase is transferred to another new RNase-free EP tube; add an equal volume of isopropanol, vortex to mix slightly, and let it stand at room temperature for 10min; centrifuge at 12,000g at 4 degrees for 20min to precipitate (RNA); 1mL of 75% ethanol, vortex, centrifuge at 16000 for 5min, repeat twice; discard the supernatant, add appropriate amount of DEPC water according to the amount of precipitate; Nandrop measures RNA concentration, A260 / 280 is 1.8-2.0, and A260 / 230 is greater than 2.0.

[0121] 6.2 Real-time fluorescence quantitative PCR:

[0122] Follow the instructions in the SYBR Green PCR Master Mix kit. The specific steps are as follows:

[0123] Prepare enough SYBR Green Master Mix to mix with forward and reverse primers for subsequent experiments. Prepare the mixture according to the system in Table 2.

[0124] Table 2 Mixed solution preparation

[0125]

[0126] Use a pipette to add 10 μL of the mixture to each well; seal the 96-well plate with sealing film and centrifuge briefly to ensure that there is no liquid residue on the tube wall; turn on the computer and Roche 480 instrument, set the program, and perform Real-time PCR reaction.

[0127] 7. Isolation of Human Peripheral Blood Mononuclear Cells

[0128] (1) Venous blood collection: 5 mL of EDTA anticoagulated venous blood was collected on an empty stomach;

[0129] (2) Ficoll centrifugation to extract PBMC:

[0130] After 5 mL of venous blood was collected, it was processed within 1 h;

[0131] Dilution: Add an equal amount of PBS to 10 mL of venous blood and mix well;

[0132] Add lymphocyte separation solution: Add 10 mL of lymphocyte separation solution (Ficoll-Paque, density 1.077) to the bottom of a 50 mL centrifuge tube, add the diluted blood into the centrifuge tube along the tube wall, and do not disturb the Ficoll liquid surface (note that the volume ratio of diluted blood to separation solution is about 2:1);

[0133] Centrifugation: 400g, room temperature, 30min, centrifuge speed adjusted to 0;

[0134] Separation: After centrifugation, there are 4 layers from the bottom of the tube to the liquid surface, which are red blood cell and granulocyte layer, stratified liquid surface, mononuclear cell layer, and plasma layer. There is a narrow white cloud-like band between the upper and middle layers, which is PBMC. Carefully aspirate the mononuclear cell layer (PBMC) and resuspend it in 10mL PBS; if serum needs to be taken at the same time, the anticoagulated blood can be pre-centrifuged at 200g for 5 minutes, and the upper layer is serum; use 2 times the volume of PBS;

[0135] Resuspend the lower layer of blood cells to further separate PBMCs;

[0136] Washing: Add 5 times the volume of PBS to the mononuclear cell suspension, mix it by pipetting repeatedly, and then centrifuge it at 200g for 15 minutes. Repeat this washing process 3 times to wash away the excess lymphocyte separation solution and red blood cells, discard the supernatant, and keep the precipitate;

[0137] (3) Stimulation and culture of PBMC: 1.1 μg / mL CD3 / CD28 antibody was coated on the plate for 4 h in advance, and then 2×10 6The cells were seeded in a 24-well plate at a density such that the final volume of the cell suspension in the well plate was 1 mL, and the stimulation was continued for 6 h.

[0138] 8. Overexpression of IRF4 in CD8 T cells

[0139] Prepare platE cells in advance and spread them into 6-well plates, so that the density reaches 70% to 80% within 12 to 24 hours, and the virus packaging is carried out when the cells are in good condition; the retrovirus packaging system is 1mL, and the system and operation are as follows: add 3.5ug of the target plasmid and 0.5ug of pcl Ecol to a 1.5mL EP tube, and add 2.5M CaCl dropwise 2 Solution 10μL, let stand for 10min; add 100μL 2×HEPES solution dropwise, shake gently, let stand for 15-20min; add the above mixture to the corresponding platE cell culture dish by cross method, shake left and right, and culture in a 37℃ incubator, and change the liquid after 8-12h; collect the virus liquid and infect the target cells (see 1.10 for specific infection steps); 36h after the liquid change, collect the virus liquid at the first time point, filter the virus liquid with a 0.45μM filter, remove platE cells and debris, and infect the target cells with the filtered virus liquid. After another 24h, collect the virus liquid at the second time point, filter it according to the above steps, and infect the target cells again.

[0140] Isolation of CTL: Kill OT-1 mice, take spleen cells, split the red blood cells, take half of the cells and filter them and resuspend them in 30mL 1640 medium in a 75ml culture flask, add 30μL 10μg / mL IL-2 (final concentration is 10ng / ml), 3μL 100μM OVA-N4 (final concentration is 10nM), mix well and add to the culture flask, place in the incubator for culture; after 24h of T cell culture, count, take 2×10^6 and resuspend in 1mL. Take a 6-well plate and add 1mL 1640 medium to the control well, add 1mL of the first wave of virus liquid collected to the experimental group, and then add 0.5mL CD8 to each well. +T cells, then add 0.5mL 1640 culture medium (containing 2μL 10μg / mL IL-2 (final concentration of 10ng / ml) and 0.2μL 100mg / mL polybrene (final concentration of 10μg / mL)), and blow evenly; seal the plate with sealing film, weigh and balance it and place it in a centrifuge at 30 degrees, 2500rpm, and infect for 2h; after centrifugation, remove the sealing film and culture the cells overnight; change the medium 12h after the second infection, and continue to culture in the incubator; 24h after the first infection, carefully aspirate 2mL of supernatant (remaining volume is 0.5mL), add 1mL 1640 full culture and 1mL collected second wave virus liquid to each well, and add 2.5μL IL2 and 1.25μL polybrene, gently shake the culture plate; seal the edge of the well with sealing film, centrifuge at 2500rpm for 2h; remove the sealing film after centrifugation, incubate at 37℃ for 12h, then replace with fresh 1640 culture medium, and perform subsequent drug intervention according to experimental needs.

[0141] Experimental Results

[0142] 1. Effect of IRF4 overexpression on the expression of GZMB, TNF-α and IFN-γ related genes in CD8 T cells

[0143] The results are as follows Figure 1 As shown, after IRF4 overexpression, GzmB + CD8 + The proportion of T cells increased, and the expression levels of TNF-α and IFN-γ related genes increased, indicating that IRF4 promotes CD8 + Cytotoxic effect of T.

[0144] 2. Empagliflozin and β-hydroxybutyrate inhibit IRF4 gene expression

[0145] The results are as follows Figure 2 As shown, the left picture shows CD8 + After 24h of intervention with 10μM empagliflozin and 10mM β-hydroxybutyrate in T cells, the mRNA level of IRF4 was significantly reduced. + After 10 μM empagliflozin and 10 mM β-hydroxybutyrate were added to T cells for 1 and 6 hours, the protein level of IRF4 was also significantly reduced.

[0146] 3. Empagliflozin and β-hydroxybutyrate inhibit IRF4 from entering the nucleus and inhibiting its transcription

[0147] The results are as follows Figure 3 As shown, the left picture shows CD8 +After 10 μM empagliflozin and 10 mM β-hydroxybutyrate were added to T cells for 1 and 6 hours, the cytoplasmic and nuclear proteins were separated and the protein levels of IRF4 were tested. It was found that these two drugs could inhibit the level of IRF4 in the nucleus. The right picture shows an immunofluorescence experiment. + After 10 μM empagliflozin and 10 mM β-hydroxybutyric acid were added to T cells for intervention for 1 hour, IRF4 protein and DAPI (indicating cell nuclei) were stained, and it was found that the expression of IRF4 in the nucleus was reduced after the intervention of empagliflozin and β-hydroxybutyric acid.

[0148] 4. Effect of empagliflozin on early activation of CD8+T cells

[0149] Flow cytometry was used to detect the effect of empagliflozin on CD8 + Effects of early T cell activation. Naive CD8 isolated from mouse spleen + After T cells were activated by CD3 / CD28 mAb for 6 hours, CD8 + CD69 + The results showed that empagliflozin can significantly inhibit CD8 + Early T cell activation Figure 4 ).

[0150] 5. Effect of Empagliflozin on CD8 + Effects of late activation and function of T cells

[0151] Flow cytometry was used to detect the effect of empagliflozin on CD8 + Effects of late activation and function of T cells; Isolation of mouse spleen naive CD8 + After T cells were activated with CD3 / CD28 mAb for 24 hours, CD8 + CD44 + Fluorescence real-time quantitative analysis was used to detect the effects of empagliflozin on the activation of CD8 T cells in the late stage. + The results showed that empagliflozin could significantly inhibit the expression of T cell inflammatory genes. + Late activation of T cells and cytotoxicity, reducing the secretion of inflammatory factors ( Figure 5 ).

[0152] 6. Effect of empagliflozin on early activated and late activated CD8 + Effect of T cell ratio

[0153] Peripheral blood was collected from a healthy subject, and peripheral blood mononuclear cells (PBMCs) were separated and plated on a cell plate pre-coated with CD3 / CD28 mAb. Empagliflozin was given for 24 hours, and surface markers CD8, CD44, and CD69 were selected for flow cytometry staining. Flow cytometry showed that Empagliflozin could significantly reduce CD8 + CD44 + and CD8 + CD69 + The results showed that empagliflozin can also reduce early activated and late activated CD8 + T cell ratio ( Figure 6 ).

[0154] 7. Effects of empagliflozin on liver lipid metabolism, inflammatory infiltration and fibrosis in MASH mice

[0155] In the MASH mouse model established by HFHC diet, empagliflozin was used for intervention, and typical pictures of liver tissue were displayed. The results showed that empagliflozin improved the lipid metabolism, inflammatory infiltration and fibrosis of the liver of MASH mice ( Figure 7 ).

[0156] 8. Effects of Empagliflozin on Liver Infiltration and Effector Function of CD8 T Cells in MASH Mice

[0157] In the MASH mouse model established by HFHC diet, the upper figure shows the immunohistochemical staining of CD8 and GZMB in the liver at the end of empagliflozin intervention, and the score is based on the immunohistochemical results. The lower figure shows the number of CD8 and GZMB positive cells per unit area under 20 times the field of view, and the liver GZMB gene expression and serum GZMB level are detected. Figure 8 As shown, empagliflozin improved CD8 T cell liver infiltration and effector function in MASH mice.

[0158] 9. Effect of β-OHB on primary CD8 + Effects of T cell activation and function

[0159] CD3 / CD28 mAb stimulation for 24 hours, and detection of CD8 after intervention with different concentrations of β-OHB + CD44 + With CD8 + GZM + T cell changes and the expression of inflammation-related genes. The results showed that β-OHB can inhibit the activation and cytotoxicity of primary CD8+T cells ( Fig. 9 ).

[0160] Effects of 1,3-BD on lipid metabolism, inflammatory infiltration and fibrosis in the liver of MASH mice

[0161] In the MASH mouse model established by HFHC feed, 1,3-BD (a precursor of β-hydroxybutyrate, which can be converted into β-hydroxybutyrate in the body) was used as a treatment. Typical pictures of liver tissue after the intervention were shown, and NAS scores and Masson staining were performed. The results showed that 1,3-BD can improve the inflammatory infiltration and fibrosis of the liver in MASH mice ( Fig.10 ).

[0162] Effects of 1,3-BD on liver infiltration and effector function of CD8 T cells in MASH mice

[0163] In the MASH mouse model established by HFHC diet, immunohistochemical staining of CD8 and GZMB in the liver was performed at the end of 1,3-BD intervention, and the number of CD8 and GZMB positive cells per unit area under 20 times the field of view was counted according to the immunohistochemical results. The results showed that 1,3-BD can significantly reduce CD8 T cell liver infiltration and effector function ( Fig.11 ).

[0164] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. Application of IRF4 inhibitors in the preparation of drugs for the treatment of non-alcoholic fatty hepatitis.

2. The use according to claim 1, It is characterized in that The IRF4 inhibitor inhibits CD8 + The activation and function of T cells regulate the abnormal immune state of the liver and achieve the purpose of treating non-alcoholic fatty hepatitis.

3. Use of IRF4 inhibitors in (1) or (2): (1) Inhibition of CD8 + T cell activation; (2) Preparation of inhibitory CD8 + Products of T cell activation.

4. Use of IRF4 inhibitors in (3) or (4): (3) Inhibit the secretion of inflammatory factors; (4) Prepare products that inhibit the secretion of inflammatory factors.

5. Use of IRF4 inhibitors in (5) or (6): (5) inhibiting the expression of GZMB; (6) Prepare products that inhibit the expression of GZMB.

6. The use according to any one of claims 1 to 5, It is characterized in that The IRF4 inhibitor is at least one of a substance that inhibits the activity of IRF4, a substance that degrades IRF4, and a substance that reduces the expression level of IRF4.

7. The use according to claim 6, It is characterized in that The substance that reduces the expression level of IRF4 is at least one of a1) to a5): a1) siRNA, dsRNA, miRNA, sgRNA, ribozyme or shRNA targeting IRF4; a2) a nucleic acid molecule encoding the siRNA, dsRNA, miRNA, sgRNA, ribozyme or shRNA targeting IRF4 described in a2); a3) an expression cassette, a vector or a transgenic cell line comprising the nucleic acid molecule described in a2); a4) Small molecule drugs targeting IRF4; a5) Blocking IRF4 protein and / or IRF4 protein intermediate IRF4 inhibitory polypeptide.

8. The use according to claim 7, It is characterized in that The substance that reduces the expression level of IRF4 includes empagliflozin and / or β-hydroxybutyric acid.

9. A non-diagnostic or therapeutic purpose of inhibiting CD8 + Methods for activating T cells, It is characterized in that The method comprises the step of + Steps in the exposure of T cells to IRF4 inhibitors.

10. Use of empagliflozin and / or β-hydroxybutyric acid in the preparation of IRF4 inhibitors.

Citation Information

Patent Citations

  • 3-hydroxybutyrate compounds for use in reducing liver fat

    WO2019002828A1